Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals?

Advances in direct‐acting antiviral treatment of HCV have reinvigorated public health initiatives aimed at identifying affected individuals. We evaluated the possible impact of only diagnosed and linked‐to‐care individuals on overall HCV burden estimates and identified a possible strategy to achieve the WHO targets by 2030.

[1]  A. Andriulli,et al.  Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas. , 2018, European journal of internal medicine.

[2]  A. Gasbarrini,et al.  Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort , 2017, Hepatology.

[3]  J. Lazarus,et al.  Micro-elimination - A path to global elimination of hepatitis C. , 2017, Journal of hepatology.

[4]  G. Ippolito,et al.  Declining unawareness of HCV‐infection parallel to declining prevalence in Southern Italy , 2017, Journal of medical virology.

[5]  J. Ward,et al.  The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination — Georgia, 2015–2016 , 2017, MMWR. Morbidity and mortality weekly report.

[6]  Gamal Esmat,et al.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[7]  Brian L. Strom,et al.  A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report , 2017 .

[8]  F. Mennini,et al.  HCV - Estimation of the number of diagnosed patients eligible to the new anti-HCV therapies in Italy. , 2016, European review for medical and pharmacological sciences.

[9]  J. Ward,et al.  National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016. , 2016, MMWR. Morbidity and mortality weekly report.

[10]  M. Hellard,et al.  Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model , 2016, Gut.

[11]  M. Shiffman.  Universal screening for chronic hepatitis C virus , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[12]  D. Solari,et al.  Bilateral hypertrophy of masseteric and temporalis muscles, our fifteen patients and review of literature. , 2016, European review for medical and pharmacological sciences.

[13]  S. Vella,et al.  PITER: An ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[14]  Carlo Torti,et al.  Update on epidemiology of HCV in Italy: focus on the Calabria Region , 2014, BMC Infectious Diseases.

[15]  N. Reau.  HCV testing and linkage to care: Expanding access , 2014, Clinical liver disease.

[16]  G. Esmat,et al.  The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm , 2014, Journal of viral hepatitis.

[17]  D. Holtzman,et al.  Previous exposure to HCV among persons born during 1945-1965: prevalence and predictors, United States, 1999-2008. , 2014, American journal of public health.

[18]  M. Hellard,et al.  Eradication of hepatitis C infection: The importance of targeting people who inject drugs , 2013, Hepatology.

[19]  M. Hellard,et al.  Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals , 2013, Hepatology.

[20]  A. Costantino,et al.  Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: evidence for a vanishing infection. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[21]  M. Buti,et al.  Predicted effects of treatment for HCV infection vary among European countries. , 2012, Gastroenterology.

[22]  M. Hellard,et al.  Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia , 2012, The Medical journal of Australia.

[23]  E. Schiff,et al.  Hepatitis C virus infection in USA: an estimate of true prevalence , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[24]  Colin W Shepard,et al.  Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.

[25]  M. Intorcia,et al.  Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. , 2000, Journal of hepatology.

[26]  C. Tiribelli,et al.  Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study , 1999, Gut.

[27]  A. Costantino,et al.  Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community‐based survey in southern Italy , 1997, Hepatology.